


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is for information purposes only and does not constitute an invitation or solicitation of an offer to acquire, purchase or subscribe for securities or an invitation to enter into an agreement to do any such things, nor is it calculated to invite any offer to acquire, purchase or subscribe for any securities.*

*This announcement and the information herein is not for distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement and the information herein does not constitute or form a part of any offer or solicitation to purchase, subscribe or sell securities in the United States. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “**Securities Act**”), or the securities laws of any state of the United States or other jurisdiction. The securities referred to herein are being offered and sold outside the United States in reliance on Regulation S under the Securities Act and may not be offered or sold within the United States absent registration or an applicable exemption from registration under the Securities Act. No public offering of the securities referred to herein will be made in the United States or in any other jurisdiction where such an offering is restricted or prohibited. No money, securities or other consideration is being solicited by this announcement or the information contained herein and, if sent in response to this announcement or the information contained herein, will not be accepted.*



**SINO BIOPHARMACEUTICAL LIMITED**  
**中國生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

*Website: [www.sinobiopharm.com](http://www.sinobiopharm.com)*

**(Stock code: 1177 and Bond code: 40150)**

**ADJUSTMENT TO CONVERSION PRICE OF  
EURO750,000,000 ZERO COUPON CONVERTIBLE BONDS DUE 2025**

Reference is made to the announcements of Sino Biopharmaceutical Limited (the “**Company**”) dated 23 January 2020, 17 February 2020, 20 July 2020, and 16 June 2021 in relation to the EURO750,000,000 zero coupon convertible bonds due 2025. Capitalised words and expressions used herein have the same meanings as those defined in the announcement of the Company dated 23 January 2020.

In accordance with the terms and conditions of the Bonds, an adjustment will be made to the Conversion Price on the date after the record date for the payment of the final dividend for the year ended 31 December 2021. The Conversion Price will be adjusted from HK\$12.56 per Share to HK\$12.41 per Share with effect from 23 June 2022. Save for the above Conversion Price adjustment, all other terms and conditions of the Bonds remain unchanged.

As at the date of this announcement, the outstanding principal amount of the Bonds is EURO489,732,000. The maximum number of Conversion Shares that will be issued upon conversion of all the outstanding Bonds at the current Conversion Price and the adjusted Conversion Price is 335,829,040 Shares and 339,888,214 Shares, respectively.

By order of the Board  
**Sino Biopharmaceutical Limited**  
**Tse, Theresa Y Y**  
*Chairwoman*

Hong Kong, 17 June 2022

*As at the date of this announcement, the Board of the Company comprises nine executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Li Yi, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive Directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.*